-
ejection fraction (HFr
EF). Risk
factors for
HFpEF include hypertension, hyperlipidemia, diabetes, smoking, and
obstructive sleep apnea.
HFpEF is characterized...
- (HFr
EF).
There is no
convincing evidence for
pharmacological treatment of
heart failure with
preserved ejection fraction (
HFpEF).
Medication for
HFpEF is...
- LVEF (
HFpEF),
Novartis funded the PARAGON-HF
trial which was
designed to
investigate the use of sacubitril/valsartan in the
treatment of
HFpEF patients...
- the
underlying cause is
heart failure with
preserved ejection fraction (
HFpEF, when part of the
heart does not fill
properly with blood),
treatments can...
-
normal or
preserved LVEF [≥50%] (
HFpEF)
moderately reduced LVEF [in the
range of 41–49%] (HFmr
EF)
reduced LVEF [≤40%] (HFr
EF)] A
chronically low ejection...
-
patients with a
common type of
heart failure,
preserved ejection fraction (
HFpEF) in a
phase III trial. Over two years,
tirzepatide reduced the risk of major...
- doi:10.1056/NEJMoa1409077. hdl:2336/552372. PMID 25176015.
Solomon SD. "
HFpEF in the ****ure: New
Diagnostic Techniques and
Treatments in the Pipeline"...
- acid HEV
hepatitis E
virus HF
heart failure HFpEF heart failure with
preserved ejection fraction HFr
EF heart failure with
reduced ejection fraction HFM...
- with
preserved ejection fraction: a
pooled analysis of the STEP-
HFpEF and STEP-
HFpEF DM
randomised trials."
Lancet 2024.
Armstrong PW,
Butler J et al...
- (2021-07-07). "Leukocyte
count and the risk of
adverse outcomes in
patients with
HFpEF". BMC
Cardiovascular Disorders. 21 (1): 333. doi:10.1186/s12872-021-02142-y...
